Barinthus Biotherapeutics plc (BRNS)
After hours:
| Previous Close | 2.3700 |
| Open | 2.3100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.1513 - 2.3300 |
| 52 Week Range | 1.6400 - 5.1000 |
| Volume | |
| Avg. Volume | 22,779 |
| Market Cap | 84.109M |
| Beta (5Y Monthly) | -0.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.20 |
GlobeNewswireBarinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, announced its financial results for the first quarter of 2024 and provided an overview of the Company’s progress. “So far in 2024 we have continued to make strides across our programs. Notably, we r
Simply Wall St.Increases to CEO Compensation Might Be Put On Hold For Now at Barinthus Biotherapeutics plc (NASDAQ:BRNS)
Key Insights Barinthus Biotherapeutics will host its Annual General Meeting on 10th of May Salary of US$610.0k is part...
- GlobeNewswire
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
Dr. Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, hematology, oncology, and infectious diseasesOXFORD, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, today an
